Lundbeck filed for FDA approval to launch Serdolect, a schizophrenia drug pulled from the European market in 1998 because of concerns about its cardiovascular effects. The EU lifted sale restrictions on the product three years ago after a study validated its safety. The Danish drugmaker is banking on Serdolect to offset sales loss from the looming patent expiration of Lexapro, a top-selling antidepressant.

Full Story:

Related Summaries